Thermo Fisher Scientific Inc.
$669.54-$19.21 (-2.8%)
Last close · Data as of Nov 20, 2026
- Market cap
- $179.1B
- P/E
- 26.7x
- EV / EBITDA
- 18.1x
- Revenue
- $44.6B
- Net margin
- 15.0%
- ROCE
- 9.4%
Price chart
Technical chartScreen technicals →+16.9% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -2.6%
- 3M
- +6.7%
- 6M
- +48.2%
- 1Y
- +16.9%
- 5Y
- +5.3%
52-week range
Day change -$19.21 (-2.8%) from $689 to $670 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in TMO, bought on each weekday since 2021.
News & filings
What Thermo Fisher Scientific filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating profit was 6.2 times interest costs.
Concerns
No concern stands out for this company on the data on file.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services.
Read moreShow less
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
- Sector
- Healthcare
- Shares outstanding
- 376.2M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $179.1B
- P/E
- 26.7x
- P/B
- 3.4x
- EV / EBITDA
- 18.1x
- EV / Sales
- 4.7x
- P/S
- 4.0x
- 52-week high
- $721.63
- 52-week low
- $438.34
Profitability
- Operating margin
- 18.2%
- Net margin
- 15.0%
- EBITDA margin
- 25.8%
- ROE
- 12.6%
- ROCE
- 9.4%
- ROA
- 6.1%
- Asset turnover
- 0.40
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $44.6B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 3.9%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -0.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 5.8%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $6.3B
Solvency
- Current ratio
- 1.89
- Debt / Equity
- 0.74
- Debt / Assets
- 0.36
- CFO / Net profit
- 1.17
- Cash / Market cap
- 5.6%
Where the revenue went
Of every $100 of FY2025 revenue, $15 was left as net income.
| From | To | Amount |
|---|---|---|
| Revenue | Cost of revenue | $26.3B |
| Revenue | Gross profit | $18.2B |
| Gross profit | Research and development | $1.4B |
| Gross profit | Selling, general and administrative | $8.7B |
| Gross profit | Operating income | $8.1B |
| Operating income | Pretax income | $7.3B |
| Operating income | Interest and other expense | $802.0M |
| Pretax income | Tax and other | $604.0M |
| Pretax income | Net income | $6.7B |
Revenue and net profit
Revenue grew 3.9% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $44.9B | $7.0B |
| FY2023 | $42.9B | $6.0B |
| FY2024 | $42.9B | $6.3B |
| FY2025 | $44.6B | $6.7B |
Cash flows
FY2025: $7.8B from operations, $6.3B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $9.2B | $6.9B |
| FY2023 | $8.4B | $6.9B |
| FY2024 | $8.7B | $7.3B |
| FY2025 | $7.8B | $6.3B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $44.6B+3.9%1Y
- EBITDA
- $11.5B-0.2%1Y
- Net profit
- $6.7B+5.8%1Y
- Cash from operations
- $7.8B-9.8%1Y
- Free cash flow
- $6.3B-13.4%1Y
- Revenue CAGR, 3Y
- -0.3%
- Net profit CAGR, 3Y
- -1.2%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $44.6B | $11.5B | $6.7B | $6.3B | 12.6% | +3.9% | +5.8% |
Monthly returns
Month-by-month returns of TMO across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $110.3B |
| Current assets | $28.7B |
| Non-current assets | $81.6B |
| Liabilities | $56.8B |
| Current liabilities | $15.2B |
| Non-current liabilities | $41.6B |
| Equity | $53.5B |
| Paid-in capital | $18.6B |
| Retained earnings | $59.2B |
| Treasury stock | $22.3B |
| Minority interest | $129.0M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; TMO highlighted.
P/E against peers
TMO trades at 26.7x earnings against a peer median of 24.2x (a 10% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc.TMOthis companyP/E ↑ premium | $179.1B | 26.7x | 3.4x | 12.6% | 18.1x |
| Amgen Inc.AMGN | $186.5B | 24.2x | 21.5x | 89.1% | 13.7x |
| Gilead Sciences, Inc.GILD | $160.4B | 18.8x | 7.1x | 37.5% | 12.9x |
| Abbott LaboratoriesABT | $158.1B | 24.2x | 3.0x | 12.5% | 13.5x |
| Intuitive Surgical, Inc.ISRG | $148.3B | 51.9x | 8.3x | 16.0% | 39.3x |
| Pfizer Inc.PFE | $146.4B | 18.8x | 1.7x | 9.0% | 12.5x |
| Danaher CorporationDHR | $132.1B | 36.6x | 2.5x | 6.9% | 21.2x |
| CVS Health CorporationCVS | $121.0B | 68.4x | 1.6x | 2.4% | 19.5x |
| Bristol-Myers Squibb CompanyBMY | $115.6B | 16.4x | 6.3x | 38.2% | 10.0x |
| Peer median | — | 24.2x | 4.6x | 14.3% | 13.6x |
Year-to-date ROI
TMO since 1 January, against earlier years.
Historical volatility
TMO's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 18.9% |
| FY2023 | 17.1% |
| FY2024 | 18.0% |
| FY2025 | 18.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $44.6B |
| Cost of revenueCost Of Revenue | $26.3B |
| Gross profitGross Profit | $18.2B |
| Operating expensesOperating Expense | $10.1B |
| Research and developmentResearch And Development | $1.4B |
| Selling, general and administrativeSelling General And Administration | $8.7B |
| Total expensesTotal Expenses | $36.4B |
| Operating incomeOperating Income | $8.1B |
| Interest and other | |
| Pretax incomePretax Income | $7.3B |
| TaxTax Provision | $547.0M |
| Net incomeNet Income | $6.7B |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $110.3B |
| Current assetsCurrent Assets | $28.7B |
| Non-current assetsTotal Non Current Assets | $81.6B |
| LiabilitiesTotal Liabilities Net Minority Interest | $56.8B |
| Current liabilitiesCurrent Liabilities | $15.2B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $41.6B |
| EquityTotal Equity Gross Minority Interest | $53.5B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $7.8B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $7.8B |
| Net income, continuing operationsNet Income From Continuing Operations | $6.7B |
| Depreciation and amortisationDepreciation And Amortization | $2.8B |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $2.8B |
| Depreciation | $1.1B |
| Amortization cash flowAmortization Cash Flow | $1.7B |
| Amortization of intangiblesAmortization Of Intangibles | $1.7B |
| Stock-based compensationStock Based Compensation | $310.0M |
| Deferred taxDeferred Tax | -$639.0M |
| Deferred income taxDeferred Income Tax | -$639.0M |
| Operating gains and lossesOperating Gains Losses | — |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Change in working capitalChange In Working Capital | -$1.8B |
| Other non-cash itemsOther Non Cash Items | $412.0M |
| Investing cash flowInvesting Cash Flow | -$4.0B |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$4.0B |
| Capital expenditureCapital Expenditure | -$1.5B |
| Purchase of PP&EPurchase Of PPE | -$1.5B |
| Sale of PP&ESale Of PPE | $44.0M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$1.5B |
| AcquisitionsPurchase Of Business | -$4.0B |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$4.0B |
| Purchase of investmentsPurchase Of Investment | -$383.0M |
| Sale of investmentsSale Of Investment | $1.8B |
| Net investment purchases and salesNet Investment Purchase And Sale | $1.4B |
| Other investing changesNet Other Investing Changes | $21.0M |
| Financing cash flowFinancing Cash Flow | $1.8B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | $1.8B |
| Debt issuedIssuance Of Debt | $8.9B |
| Debt repaidRepayment Of Debt | -$3.5B |
| Net debt issuedNet Issuance Payments Of Debt | $5.3B |
| Short-term debt issuedShort Term Debt Issuance | $1.1B |
| Short-term debt repaidShort Term Debt Payments | -$1.1B |
| Net short-term debt issuedNet Short Term Debt Issuance | $0.00 |
| Long-term debt issuedLong Term Debt Issuance | $7.8B |
| Long-term debt repaidLong Term Debt Payments | -$2.4B |
| Net long-term debt issuedNet Long Term Debt Issuance | $5.3B |
| Net common stock issuedNet Common Stock Issuance | -$3.0B |
| Common stock repurchasedCommon Stock Payments | -$3.0B |
| Share buybacksRepurchase Of Capital Stock | -$3.0B |
| Stock options exercisedProceeds From Stock Option Exercised | — |
| Dividends paidCash Dividends Paid | -$636.0M |
| Other financing chargesNet Other Financing Charges | $90.0M |
| Change in cashChanges In Cash | $5.6B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 26,700.0% |
| Cash at the start of the yearBeginning Cash Position | $4.0B |
| Cash at the end of the yearEnd Cash Position | $9.9B |
| Free cash flowFree Cash Flow | $6.3B |
| Supplemental |
Learn while you research
Academy chapters picked for Thermo Fisher Scientific Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 03 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 04 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read